Search

Vladimir Zah,1 Rowe B Brookfield,2 Martina Imro,1 Simona Tatovic,1 Jovana Pelivanovic,1 Djurdja Vukicevic1 1Health Economics and Outcomes Research Department, ZRx Outcomes Research Inc, Mississauga, Ontario, Canada; 2Field Medical Affairs, Depomed, Inc, Newark, CA, USACorrespondence: Vladimir ZahHealth Economics and Outcomes Research Department, ZRx Outcomes Research Inc., 3373 Cawthra Road, Mississauga, Ontario, CanadaTel/fax +14169534427Email vzah@outcomesresearch.caPurpose: Chronic pain treatment imposes a substantial economic burden on US society. Treatment costs may vary across subgroups of patients with different types of pain. The aim of our study was to compare healthcare costs (HC) and resource utilization in musculoskeletal (MP), neuropathic (NP), and cancer pain (CaP) patients treated with long-acting opioids (LAO), using real-world evidence.Patients and methods: We compared total HC and resource utilization in subgroups of chronic pain patients (MP, NP or CaP) treated with three LAO alternatives: morphine-sulfate extended-release (MsER), oxycodone ER (OxnER) and tapentadol ER (TapER). Retrospective claims data were analyzed in the IBM Truven Health MarketScan® Commercial Claims Database (October 2012 through March 2016). All patients were continuously health plan enrolled for at least 12 months before the index date (first LAO prescription date) and during the LAO-treatment period. The cohorts were propensity-score matched.Results: A total of 2824 TapER-treated patients were matched to 16,716 OxnER-treated patients, while 2827 TapER patients were matched to 16,817 MsER patients. The average monthly total HC were lower in the TapER than in the OxnER cohort ($2510 vs. $3720, p